MarginsXMarginsX
Home › Markets › Health Care › RNA

Atrium Therapeutics Inc. (RNA)

RNA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.43
-14.38% on the day
Market cap
$138.7M
Micro cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerRNA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0002093101
SEC industry codePharmaceutical Preparations

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
9.0 months
$44.6M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$44.6M cash; operating cash flow -$14.8M a quarter.Report 2026-09-30
Shares outstanding21,571,507 (2026-11-02).Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$15.3M-$4.3M-$25.4M$44.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
$3.0M-$20.2M-$3.9M$72.3MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
$19.6M-$16.6M-$31.1M$267.8MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q3 2026
2025-09-30
$12.3M-$37K$1.1M$0No debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2025-06-30
$3.8M-$12.9M-$11.9M$0No debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2025-03-31
$1.6M-$7.4M-$11.1M$0No debt tagsNeeds four quarters10-Q 2026-05-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 61 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.0%
1 month-3.1%
3 months-39.1%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-54.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MGNXMacroGenics Inc.$2.17-1.36%$138.7M
MSLESatellos Bioscience Inc.$6.47-2.34%$137.3M
SIONSionna Therapeutics Inc.$3.12-6.31%$141.1M
MENSJyong Biotech Ltd.$1.77+0.57%$134.6M
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
CNTNCanton Strategic Holdings Inc.$1.64-4.09%$130.7M
VRXAVeraxa Biotech AG$1.04-5.86%$147.8M
ABEOAbeona Therapeutics Inc.$2.60+7.44%$148.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier